Landscapes / Companies
EyeBiotech Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
Drugs
2
in active trials
Trials
5 active
7 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Multi-specific immunoglobulin |
Phase 2/3 | 11 Jan 2027Phase 2/3 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 11 Jan 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD) and 1 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Jun 2028Phase 2/3 trial completes | |||
| Next date | 30 Jun 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Macular Degeneration, Age-Related Macular Degeneration and 2 more | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021